OncoMatch/Clinical Trials/NCT06542159
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
Is NCT06542159 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for adaptive radiotherapy.
This study aims to explore the safety and efficacy of eliminating the PTV (planning target volume) margins based on online adaptive stereotactic radiotherapy for patients with early-stage non-small cell lung cancer (NSCLC) or pulmonary oligometastases.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
serum hemoglobin ≥ 80 g/l, platelets ≥ 100,000/μl, absolute neutrophil count ≥ 1,500/μl
Kidney function
serum creatinine ≤ 1.25 times the upper normal limit (unl) or creatinine clearance ≥ 60 ml/min
Liver function
serum bilirubin ≤ 1.5 times unl, ast (sgot) and alt (sgpt) ≤ 2.5 times unl, alkaline phosphatase ≤ 5 times unl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify